Champions Oncology Says New Xenograft Models Will Aid Prostate Cancer Research

Champions Oncology Says New Xenograft Models Will Aid Prostate Cancer Research
Champions Oncology has added new cohorts of patient-derived xenograft (PDX) models to its TumorBank, expanding the company's product line in castrate-resistant prostate cancer (CRPC) and other ailments. The new PDX models will support drug development in oncology programs and in translational industry and academic research. CRPC is a type of prostate cancer that no longer responds to hormone (ADT) therapy and is continuing to progress. Besides CRPC, the models will be available for hepatocellular cancer, breast cancer, head and neck cancer, acute myeloid leukemia (AML) and non-small cell lung cancer (NSCLC). With this addition, Champions’ TumorBank grows to more than 900 clinically relevant PDX models — 160 of them added in the past
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *